GRI Bio, Inc. (GRI) - Dilution Analysis

10-Q filing | 1.8M shares outstanding

10-K filing | 1.4M shares outstanding

8-K filing: Stock split 1-for-28 | Outstanding: 2,515,305 → 89,832

8-K filing: The Company completed a public offering of common stock and warrants for gross proceeds of approximately $8.0 million. ($24.0M proceeds)

8-K filing: GRI Bio, Inc. commenced a public offering of common stock, pre-funded warrants, and Series F warrants, with the offering anticipated to close on or about December 12, 2025.

10-Q filing | 2.5M shares outstanding

10-Q filing | 2.1M shares outstanding

8-K filing: GRI Bio, Inc. commenced a public offering of 202,000 shares of common stock, 1,186,888 pre-funded warrants, 1,388,888 Series E-1 warrants, 1,388,888 Series E-2 warrants, and 1,388,888 Series E-3 warrants, with the combined offering price for each share and accompanying warrants being $3.60 and $3.5999 for each pre-funded warrant and accompanying warrants, expecting net proceeds of approximately $4.2 million.

S-1/A filing: The filing is an S-1/A and pertains to the offering of common stock, warrants, and pre-funded warrants.

S-1 filing: The filing is an S-1 registration statement for an offering of common stock, warrants (Series E-1, E-2, and E-3), and pre-funded warrants.

10-K filing | 0.5M shares outstanding

8-K filing: Stock split 1-for-17 | Outstanding: 2,927,707 → 172,149

10-Q filing | 8.9M shares outstanding

S-3 filing: This S-3 filing registers shares of common stock for offering by selling stockholders, potentially including shares issued upon exercise of warrants, with proceeds from warrant exercises going to working capital and general corporate purposes; the selling stockholders may offer and sell up to 1,577,829 shares of Common Stock.

8-K filing: GRI Bio, Inc. completed an offering where holders of Series B-1 and Series B-2 warrants exercised their warrants to purchase 762,236 shares of common stock at a reduced price of $1.00 per share, resulting in gross proceeds of $762,236 for the Company. ($0.76M proceeds)

10-Q filing | 2.9M shares outstanding

8-K filing: GRI Bio, Inc. commenced a public offering of 60,000 shares of common stock, 2,125,793 pre-funded warrants, 2,185,793 Series C-1 warrants and 2,185,793 Series C-2 warrants at a price of $1.83 per share or pre-funded warrant, with net proceeds of approximately $3.2 million.

S-1/A filing: This S-1/A filing includes an offering of common stock, Series C-1 warrants, Series C-2 warrants, pre-funded warrants, and placement agent warrants.

S-1/A filing: This S-1/A filing relates to an offering of common stock, Series C-1 warrants, Series C-2 warrants, and pre-funded warrants, as well as placement agent warrants.

S-1 filing: This S-1 filing details an offering of common stock, warrants to purchase common stock, and pre-funded warrants. It also includes placement agent warrants.

8-K filing: Stock split 1-for-13 | Outstanding: 3,196,488 → 245,883

10-Q filing | 4.1M shares outstanding

S-3 filing: This S-3 filing registers an indeterminate number of shares of common stock and preferred stock, as well as debt securities, that may be issued upon conversion or exchange of other securities, exercise of warrants or rights, or pursuant to anti-dilution provisions. It also includes shares issuable as a result of stock splits, stock dividends, or similar transactions.

10-K filing | 3.2M shares outstanding

8-K filing: GRI Bio, Inc. entered into a securities purchase agreement to issue and sell 330,450 shares of common stock, 4,669,550 pre-funded warrants exercisable for 4,669,550 shares, 5,000,000 Series B-1 common warrants exercisable for 5,000,000 shares, and 5,000,000 Series B-2 common warrants exercisable for 5,000,000 shares in a public offering for a combined purchase price of $1.10 per share/warrant.

S-1/A filing: The company is filing an S-1/A to offer up to 3,871,467 shares of common stock, pre-funded warrants, Series B-1 common warrants, and Series B-2 common warrants, with an assumed combined public offering price of $2.066 per share and accompanying warrants.

S-1/A filing: This S-1/A filing, dated 2024-01-31, relates to an offering of up to 3,871,467 shares of common stock, pre-funded warrants to purchase up to 3,871,467 shares of common stock, Series B-1 common warrants to purchase up to 3,871,467 shares of common stock, and Series B-2 common warrants to purchase up to 3,871,467 shares of common stock.

8-K filing: Stock split 1-for-7 | Outstanding: 3,246,354 → 463,764

S-1 filing: The company is offering common stock, pre-funded warrants, and common warrants on a reasonable best efforts basis.

S-1/A filing: The filing relates to the offer and resale of 4,134,201 shares of common stock by the selling stockholder, which includes shares issuable upon the exercise of various warrants.

10-Q filing | 3.2M shares outstanding

S-3 filing: This is an S-3 filing for a secondary offering of common stock by a selling stockholder. Up to 4,134,201 shares of common stock may be offered. The company will not receive any proceeds from the sale of shares but may receive up to $56,367,395 from the exercise of warrants.

10-Q filing | 3.0M shares outstanding

S-3 filing: This S-3 filing registers shares of common stock for resale by a selling stockholder, which are underlying warrants. The company will not receive proceeds from the sale of these shares, but may receive up to $16,837,339 from warrant exercises.

10-Q filing | 2.9M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 13,482,342 → 449,411

10-K filing | 13.5M shares outstanding

8-K filing: Vallon Pharmaceuticals entered into a merger agreement with GRI Bio, Inc., involving a pre-merger financing and a proposal for a reverse stock split of Vallon's common stock prior to the merger.

10-Q filing | 12.1M shares outstanding

10-Q filing | 10.5M shares outstanding

S-1 filing: Resale of 3,700,000 shares of common stock issuable upon exercise of outstanding warrants.

8-K filing: Vallon Pharmaceuticals closed on an offering and private placement of 3,700,000 shares of common stock at a price of $1.0632 per share, generating gross proceeds of approximately $3.9 million, and also amended its bylaws regarding quorum and voting requirements. ($3.9M proceeds)

8-K filing: Vallon Pharmaceuticals, Inc. entered into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. for a registered direct offering of up to 3,700,000 shares of common stock at a purchase price of $1.0632 per share, and entered into a Securities Purchase Agreement with certain investors for aggregate gross proceeds of approximately $3.9 million. ($3.9M proceeds)

10-Q filing | 6.8M shares outstanding

S-3 filing: The filing is for a shelf offering of common stock, preferred stock, warrants, debt securities, purchase contracts, units, or any combination of these securities.

10-K filing | 6.5M shares outstanding

10-Q filing | 6.8M shares outstanding

10-Q filing | 6.8M shares outstanding

10-Q filing | 6.8M shares outstanding

8-K filing: Vallon Pharmaceuticals completed a public offering of common stock, issued warrants to the representative, and executed a 1-for-40 reverse stock split. ($18.0M proceeds)

S-1/A filing: This is an S-1/A filing for an offering of common stock underwritten by ThinkEquity. The company is offering 1,670,000 shares of common stock with an option for the underwriters to purchase an additional 250,500 shares.

S-1/A filing: This is an S-1/A filing for an offering of common stock with an over-allotment option, intended to be listed on The Nasdaq Capital Market under the symbol "VLON."

S-1/A filing: This is an S-1/A filing for an offering of common stock underwritten by ThinkEquity.

S-1 filing: This S-1 filing describes a company offering shares of its common stock. It includes details about an underwriter option for additional shares, the intended use of proceeds, risk factors, dividend policy, and the proposed trading market symbol.